STOCK TITAN

Dr. Mukesh Prasad joins Cantor Equity Partners II (NASDAQ: CEPT) board

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cantor Equity Partners II, Inc. appointed Dr. Mukesh Prasad to its board of directors as a Class II director, effective May 8, 2026. He was also named to the board’s audit and compensation committees.

Dr. Prasad, age 55, is Founder and Co-Managing Partner of Innova Capital Partners and an Otolaryngologist and Associate Professor at Weill Cornell Medical College. He will receive $50,000 per year, paid quarterly, for board service.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Effective appointment date May 8, 2026 Date Dr. Mukesh Prasad joined the board as a Class II director
Director age 55 years Age of Dr. Mukesh Prasad at time of appointment
Board compensation $50,000 per year Annual compensation for Dr. Prasad’s board service, paid quarterly
Innova leadership start Since 2014 Dr. Prasad has served as Founder and Co-Managing Partner of Innova Capital Partners
Weill Cornell service Since 2002 Dr. Prasad has practiced and served as Associate Professor at Weill Cornell Medical College
Council on Foreign Relations membership Since 2015 Membership tenure for Dr. Prasad
Class II director financial
"Dr. Prasad will serve as a Class II director."
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
audit committee financial
"the Board appointed Dr. Prasad as a member of the audit committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
compensation committee financial
"and a member of the compensation committee of the Board."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers;"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Operating Board financial
"Dr. Prasad also served on the institution’s Operating Board, Finance Committee,"
Finance Committee financial
"served on the institution’s Operating Board, Finance Committee, and as Chair"
A finance committee is a small group of board members or senior managers tasked with overseeing an organization’s financial planning, budgeting, capital allocation and reporting. Think of it as the company’s household finance team that sets spending priorities, checks financial controls and advises on big investments; its quality and decisions matter to investors because they shape cash use, risk management and the credibility of financial information investors rely on.
false 0002034269 0002034269 2026-05-08 2026-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 8, 2026 (May 8, 2026)

 

CANTOR EQUITY PARTNERS II, INC.

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-42630   98-1576521
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

110 East 59th Street

New York, NY 10022

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (212) 938-5000

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary shares, par value $0.0001 per share   CEPT   The Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d) Appointment of Directors.

 

Effective May 8, 2026, the board of directors (the “Board”) of Cantor Equity Partners II, Inc. (the “Company”) appointed Dr. Mukesh Prasad as a member of the Board. Dr. Prasad will serve as a Class II director. Additionally, effective May 8, 2026, the Board appointed Dr. Prasad as a member of the audit committee of the Board and a member of the compensation committee of the Board.

 

Dr. Prasad, age 55, is an accomplished executive with comprehensive experience in finance, investing and medicine. Since 2014, Dr. Prasad has served as Founder and Co-Managing Partner of Innova Capital Partners (“Innova”), a private global investment firm with a strategy predicated on identifying disruptive innovations. Dr. Prasad is responsible for the strategic growth and capital resources for Innova. Dr. Prasad has also served as a director of Cantor Equity Partners V, Inc. since November 2025. Dr. Prasad is also an Otolaryngologist at Weill Cornell Medical College, where he has practiced and served as Associate Professor of Clinical Otolaryngology and Head and Neck Surgery since 2002. Dr. Prasad also served on the institution’s Operating Board, Finance Committee, and as Chair of the Weill Cornell General Faculty Council from 2016 to 2018. Dr. Prasad obtained his bachelor’s degree, with honors, in Government from Harvard College, with a focus on Economic and Social Policies, and a Doctorate in Medicine from The Johns Hopkins College of Medicine. Dr. Prasad completed his Otolaryngology and Head & Neck Surgery training at New York Presbyterian and Memorial Sloan Kettering Hospitals. Dr. Prasad has been a Member of the Council on Foreign Relations since 2015. The Company believes that Dr. Prasad is qualified to serve as a member of the Board due to his extensive experience in finance and investing.

 

In connection with the appointment of Dr. Prasad, the Board approved the compensation to be paid to Dr. Prasad for serving as a member of the Board of $50,000 per year, paid quarterly.

 

There are no family relationships between Dr. Prasad and any director, executive officer, or person nominated or chosen by the Company to become an executive officer of the Company.

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 8, 2026

 

  ANTOR EQUITY PARTNERS II, INC.
   
  By: /s/ Brandon G. Lutnick
  Name:  Brandon G. Lutnick
  Title: Chief Executive Officer

 

 

[Signature Page to Form 8-K of Cantor Equity Partners II, Inc. – Appointment of Dr. Mukesh Prasad as Director]

 

2

 

FAQ

What did Cantor Equity Partners II, Inc. (CEPT) announce about its board?

Cantor Equity Partners II, Inc. appointed Dr. Mukesh Prasad to its board as a Class II director, effective May 8, 2026. He also joined the audit committee and the compensation committee, expanding his governance role at the company.

Who is Dr. Mukesh Prasad, the new director at Cantor Equity Partners II (CEPT)?

Dr. Mukesh Prasad is an executive and physician with experience in finance, investing, and medicine. He is Founder and Co-Managing Partner of Innova Capital Partners and an Otolaryngologist and Associate Professor at Weill Cornell Medical College, where he has practiced since 2002.

What board committees will Dr. Mukesh Prasad serve on at CEPT?

Dr. Mukesh Prasad will serve on Cantor Equity Partners II, Inc.’s audit committee and compensation committee. These assignments give him oversight roles in the company’s financial reporting processes and executive compensation decisions as part of the board’s governance structure.

How will Cantor Equity Partners II (CEPT) compensate Dr. Mukesh Prasad as a director?

Cantor Equity Partners II, Inc. approved annual compensation of $50,000 for Dr. Mukesh Prasad’s board service. This amount will be paid quarterly and reflects his role as a director, separate from his external professional positions and responsibilities.

Are there any disclosed family relationships involving Dr. Mukesh Prasad at CEPT?

The company states there are no family relationships between Dr. Mukesh Prasad and any director, executive officer, or person nominated or chosen to become an executive officer. This disclosure highlights independence from familial ties in his board appointment.

Filing Exhibits & Attachments

3 documents